Skip to main content

White Papers and Case Studies

A Collection of our Most Read WhitePapers & Case Studies

Got a Question? Contact Us
How CluePoints Enabled Pfizer's 'Hyperspeed' Vaccine Development
Leveraging Risk-Based Quality Management to Facilitate Early Risk Detection
How CluePoints Detected Fraudulent Reporting of Investigational Product Administration from Patient Diary Data
Using CluePoints to Detect Anomalies in Electronic Patient-Reported Outcomes
Using CluePoints to Identify Severe Propagation in Vital Sign Measurements
Using CluePoints to Identify Fraud Due to the Fabrication of Patient Diaries
Using CluePoints to Detect Miscalibrated Equipment in a Clinical Trial
The Value of the CluePoints Solution in Identifying Under-reported Adverse Effects in a Clinical Trial
Using CluePoints to Reveal Protocol Deviations in Patient Selection
Examining the Current State of ICH E6 (R2) Adoption
From RBM to RBQM: The Future of Risk-Based Trial Management
Harnessing CSM to Drive Risk-Based Quality Management (RBQM)
Conclusions from Executive Roundtable on Response to ICH E6 (R2)
The Evolution of Clinical Data Management to Clinical Data Science
Implementing a Scalable Risk-Based Monitoring Strategy
Sponsor Responses to the ICH E6 Revisions
The Principles of Central Statistical Monitoring
Ensuring Trial Validity by Data Quality Assurance and Diversification of Monitoring Methods
All you need to know about SMART™, the Engine that Drives CluePoints

Got a Question?

Whether you’re looking to get started or need support, we’re here to help!

Featured Whitepaper

ICH E6 (R2)

Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.

Learn More

Featured Webinar

ICH E6 (R2)

This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.

Learn More

We're Kind of a Big Deal.


Platform Users


Studies De-Risked


Issues Detected